Peter Hodson Delcath Systems DCTH-Q TOP PICK Jul 22, 2010

Liver cancer treatment. They isolate the liver and then pump more chemo to kill cancer cells. Survivor rate has gone from 4 to 23 months. Market potential is about 5-6 billion globally. Stock dropped when a scientist said it wouldn't work but FDA protocol showed results were significant.

Peter Hodson

Owned

Unlock Rating

$7.430

Stock price when the opinion was issued

Consumer Products

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

COMMENT

Will have an FDA decision in July. Whether they get approval or not, there will be a huge move up or down. Options strategy? Market knows this is going to have an impact so this gets priced into the options. Very difficult to do this.

Most Recent Experts

Eric Nuttall

Ninepoint Partners

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Cramer - Mad Money

CNBC

Darren Sissons

Campbell Lee & Ross

Stockchase Insights

5i Research

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Peter Hodson Delcath Systems DCTH-Q TOP PICK Jul 22, 2010

You might be interested:

Delcath Systems(DCTH-Q)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals